Test Price
2,800 AED✅ Home Collection Available
DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين DNAAF3 للخلل الهدبي الأولي من النوع الثاني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ملخص تنفيذي: تحليل DNAAF3 الجيني لتشخيص خلل الأهداب الأولي بدقة تشخيصية 99.9%، بفحص NGS المتطور تحت مظلة هيئة الصحة بدبي و ISO 9001:2015.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
- ✓ Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance by DHA-Licensed Specialists.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Fully compliant with UAE Federal Decree-Law No. 41 of 2024 (Art. 87), CDS Law 2026 (Minors), and UAE PDPL.
Overview
The DNAAF3 gene test detects mutations causing primary ciliary dyskinesia type 2 (PCD2) – a rare, autosomal recessive disorder that impairs motile cilia, leading to chronic upper and lower respiratory infections, sinusitis, bronchiectasis, and laterality defects. (يكشف تحليل جين DNAAF3 عن الطفرات المسببة لخلل الأهداب الأولي من النوع الثاني، ما يؤدي إلى التهابات تنفسية مزمنة وتشوهات جانبية.)
| Feature | Our NGS Test (DNAAF3) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% analytical sensitivity, full gene coverage | Up to 99%, but limited to known variants |
| Methodology | NGS (Next Generation Sequencing) on Illumina NovaSeq X Plus | Capillary electrophoresis-based Sanger sequencing |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Variant Detection | All coding exons, splice sites, deep intronic regions | Targeted mutations only |
Pre‑Test Information
Provide a detailed clinical history of the patient suspected to have primary ciliary dyskinesia (chronic wet cough, neonatal respiratory distress, recurrent otitis media, situs inversus). A genetic counseling session to draw a pedigree chart of family members potentially affected with PCD is strongly recommended. No fasting or medication changes are required—do not discontinue prescribed medications without consulting your physician. Samples accepted: Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA card.
Physician Insight & Safety Protocol
“As a DHA-licensed clinical pathologist, I emphasize that while this NGS test provides high-resolution genetic confirmation of DNAAF3-related primary ciliary dyskinesia, results must always be correlated with clinical presentation, high-speed video microscopy, and nasal nitric oxide levels. A negative report does not exclude other PCD genes, and a multidisciplinary team—including ENT, pulmonology, and genetics—is essential to guide lifelong management.”
— Dr. PRABHAKAR REDDY, DHA License: 61713011
⚠ Medication Warning
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with severe coagulopathies or active uncontrolled bleeding should inform the phlebotomist; a dried blood spot alternative is suitable.
- ER Red Flags: Seek immediate medical attention if you experience excessive bleeding, fainting, or signs of infection (redness, swelling, fever) at the collection site post‑draw.
- This genetic test is diagnostic but not intended for acute management of respiratory distress—call emergency services if breathing difficulties worsen.
Patient FAQ & Clinical Guidance
Q1: What is the DNAAF3 gene test and why is it ordered?
ما هو تحليل جين DNAAF3 ولماذا يُطلب؟
First‑line answer: This NGS test detects disease‑causing mutations in the DNAAF3 gene to confirm a diagnosis of primary ciliary dyskinesia type 2, a genetic disorder that disrupts motile cilia and causes chronic lung, sinus, and ear infections.
يحدد هذا الفحص الطفرات المسببة للمرض في جين DNAAF3 لتأكيد تشخيص خلل الأهداب الأولي من النوع الثاني، وهو اضطراب وراثي يعطل الأهداب الحركية ويؤدي إلى التهابات رئوية وجيوب أنفية مزمنة.
Physicians order this test for children and adults with unexplained chronic respiratory problems, situs inversus, or a family history of PCD. A positive result guides targeted therapies, fertility counseling, and specialist follow‑up.
Q2: How accurate and comprehensive is this NGS compared to older methods?
ما مدى دقة وشمولية فحص NGS مقارنة بالطرق القديمة؟
First‑line answer: With 99.9% analytical sensitivity and full coverage of all coding exons and critical regulatory regions, our NGS platform identifies virtually every clinically relevant variant in DNAAF3, outperforming targeted Sanger sequencing which may miss novel or deep‑intronic mutations.
بحساسية تحليلية تبلغ 99.9% وتغطية كاملة لجميع الإكسونات والمناطق التنظيمية الحرجة، يحدد منصة NGS لدينا جميع المتغيرات ذات الصلة سريريًا في DNAAF3، متفوقًا على تقنية سانغر التي قد تفوت طفرات جديدة.
Validation studies against Sanger sequencing and clinical databases confirm that this approach yields <1% false‑negative rate, making it the gold standard for molecular diagnosis of primary ciliary dyskinesia type 2 in 2026.
Q3: What should I expect after sample collection, and how will I receive my results?
ماذا أتوقع بعد جمع العينة وكيف سأحصل على النتائج؟
First‑line answer: After a painless blood or dried spot collection by our DHA‑licensed phlebotomist, your sample is transported via cold‑chain logistics to our ISO‑certified lab; a comprehensive report will be ready in 3–4 weeks, delivered securely online with optional telephonic interpretation by a genetic specialist.
بعد جمع عينة الدم أو بقعة الورق الجاف غير المؤلم من قبل فني معتمد من هيئة الصحة، تُنقل العينة بسلسلة تبريد إلى مختبرنا الحاصل على شهادة ISO؛ يصدر تقرير شامل خلال 3-4 أسابيع ويسلم إلكترونيًا مع إمكانية الاستشارة الهاتفية من أخصائي الجينات.
You will receive an email notification to download the report from a secure patient portal. Our support team is available on WhatsApp at +971 54 548 8731 for any follow‑up questions or to schedule a tele‑genetics session.
DHA Facility License: 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | 24/7 WhatsApp: +971 54 548 8731
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians